Volumetric Absorptive Microsampling of Blood for Untargeted Lipidomics
Marasca et al.
The finding, in our words
This proof-of-concept study compared VAMS and dried blood spot microsamples with fluid blood for untargeted lipidomic profiling using high-resolution LC-MS/MS, finding that VAMS is a viable option for untargeted lipidomics with the advantage of haematocrit independence over traditional dried blood spots.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
The study validated an LC-MS/MS method for eight antiepileptic drugs and two metabolites in dried blood spot and VAMS formats, with satisfactory analytical performance and stability, and was the first to include the oxcarbazepine metabolite DHCB. In 80 paired patient samples, microsampling concentrations showed promising correlation with plasma, supporting decentralised therapeutic drug monitoring of antiepileptic treatment.
This study compared four dried blood spot devices for glucocorticoid detection, finding that the Mitra VAMS device offered the best combination of analytical recovery and user usability, whilst the HemaXis DB10 showed the least bias compared to whole blood.
A comparison of three patient-centric dried blood microsampling devices, paper DBS, Mitra and Tasso-M20, found strong to excellent correlation with traditional venous plasma for measuring branched-chain amino acids and ketoacids. Participants reported high acceptability and expressed a strong willingness to use these devices for decentralised self-collection.
In an untargeted metabolomics study, microsampling devices, particularly the Mitra and Capitainer, yielded metabolic profiles comparable or superior to plasma in feature number and intensity, and in the precision and stability of some metabolites. This supports their potential for large-scale, decentralised metabolic profiling, though the captured metabolite profile was application-dependent.